Skip to main content
. 2016 Aug 19;7(39):63003–63019. doi: 10.18632/oncotarget.11416

Figure 2. Ciclopirox impairs S phase progression of Ewing sarcoma cells.

Figure 2

A. Four Ewing sarcoma cell lines were treated with ciclopirox (10 μM) for 24 hours and then fixed to analyze their cell cycle distribution using propidium iodide. B. Cell cycle analysis with EdU and propidium iodide shows that treatment with ciclopirox (10 μM) results in a mixture of replicating and non-replicating (dotted box) S phase cells. C. Treatment of Ewing sarcoma cell lines with ciclopirox (10 μM) for 24 hours causes a reduction in dATP and dCTP levels. D. Quantification of ssDNA, using a non-denaturing BrdU assay, in cells treated with ciclopirox (10 μM). E., F. Western blots showing that treatment of Ewing sarcoma cell lines with ciclopirox (10 μM) causes phosphorylation of RPA32 E. and Chk1 F.